Novo Nordisk is preparing to file for approval of an oral Wegovy (semaglutide pill) in China, a market where injectable drug penetration faces cultural and logistical headwinds that an oral formulation directly addresses. NVO already runs 81% gross margins on its GLP-1 franchise and posted 6.4% revenue growth to ~$309B in FY2025, but growth has slowed from the hypergrowth phase as U.S. and European market penetration matures — making China a key next frontier.

The China approval timeline is uncertain and could stretch 18–36 months, while domestic Chinese pharma companies are aggressively developing competing GLP-1 drugs at lower price points. Investors should watch for any official filing date announcement, the pace of NMPA review, and whether local competitors (e.g. Innovent, Hengrui) announce pill-form GLP-1 data that could undercut NVO's first-mover window.